Rubius Therapeutics Inc


Prices are adjusted according to historical splits.

Rubius Therapeutics Inc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$1.85 million
Book Value:
Revenue TTM:
Operating Margin TTM:
Gross Profit TTM:
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Rubius Therapeutics Inc had its IPO on 2018-07-18 under the ticker symbol RUBY.

The company operates in the Healthcare sector and Biotechnology industry. Rubius Therapeutics Inc has a staff strength of 6 employees.

Stock update

Shares of Rubius Therapeutics Inc opened at $0.02 at the start of the last trading session i.e. 2023-05-28.

The stocks traded within a range of $0.02 - $0.02, and closed at $0.02.

This is a +17.92% increase from the previous day's closing price.

A total volume of 57,661 shares were traded at the close of the day’s session.

In the last one week, shares of Rubius Therapeutics Inc have increased by +9.68%.

Rubius Therapeutics Inc's Key Ratios

Rubius Therapeutics Inc has a market cap of $1.85 million, indicating a price to book ratio of 0.4199 and a price to sales ratio of 0.

In the last 12-months Rubius Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-120995000. The EBITDA ratio measures Rubius Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Rubius Therapeutics Inc’s operating margin was 0% while its return on assets stood at -46.63% with a return of equity of -185.31%.

In Q4, Rubius Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Rubius Therapeutics Inc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-2.35 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Rubius Therapeutics Inc’s profitability.

Rubius Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.1116. Its price to sales ratio in the trailing 12-months stood at 0.

Rubius Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$23.07 million
Total Liabilities
$7.94 million
Operating Cash Flow
Capital Expenditure
Dividend Payout Ratio

Rubius Therapeutics Inc ended 2023 with $23.07 million in total assets and $0 in total liabilities. Its intangible assets were valued at $23.07 million while shareholder equity stood at $15.13 million.

Rubius Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $7.94 million in other current liabilities, 90000.00 in common stock, $-856684000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $14.87 million and cash and short-term investments were $18.94 million. The company’s total short-term debt was $1,100,000 while long-term debt stood at $0.

Rubius Therapeutics Inc’s total current assets stands at $20.20 million while long-term investments were $0 and short-term investments were $4.07 million. Its net receivables were $0 compared to accounts payable of $1.23 million and inventory worth $0.

In 2023, Rubius Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $266000.

Comparatively, Rubius Therapeutics Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Rubius Therapeutics Inc stock is currently trading at $0.02 per share. It touched a 52-week high of $1.57 and a 52-week low of $1.57. Analysts tracking the stock have a 12-month average target price of $1.

Its 50-day moving average was $0.02 and 200-day moving average was $0.27 The short ratio stood at 0.49 indicating a short percent outstanding of 0%.

Around 549.8% of the company’s stock are held by insiders while 5368.8% are held by institutions.

Frequently Asked Questions About Rubius Therapeutics Inc

The stock symbol (also called stock or share ticker) of Rubius Therapeutics Inc is RUBY

The IPO of Rubius Therapeutics Inc took place on 2018-07-18

Similar Industry Stocks (Biotechnology)

Last Price

Most Active

Last Price
Tesla Inc (TSLA)

Top Gainers

Last Price
Boxed Inc (BOXD)

Top Losers

Last Price


Rubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, Inc and as changed its name to Rubius Therapeutics, Inc. in 2015. Rubius Therapeutics, Inc. was incorporated in 2013 and is based in Foxborough, Massachusetts.


399 Binney Street, Cambridge, MA, United States, 02139